Clinical Trial

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is an open label phase 2 study to evaluate the safety and efficacy of Lenvatinib with Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the neoadjuvant / adjuvant treatment for Patients with Gastric Cancer.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2021-02-08; most recent amendment 2026-04-06.
Status change: Recruiting → Active, Not Recruiting 2024-11-13
Status change: Not Yet Recruiting → Recruiting 2021-11-24
Trial Details
NCT Number NCT04745988
Lead Sponsor National Cancer Center Hospital East
Collaborators: Merck Sharp & Dohme LLC
Conditions Gastric Cancer
Enrollment 43 participants
Start Date 2021-11-11
Primary Completion 2026-08 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-04-09